Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation

Similar documents
Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

The Pharmacovigilance Quality System. What is it?

Pharmacovigilance System Master file

Quality Risk Management

Pharmacovigilance Inspection Metrics Report

Competence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014)

Good Documentation Practice Session 2

Module VIII- Post-authorisation safety studies

Guideline on good pharmacovigilance practices (GVP)

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)

New pharmacovigilance systems and services

Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories

Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety

Building Quality Metrics. Mark Birse, Deputy Director & Head of Inspectorate

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

Agenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

Detecting Drug Safety Signals from Spontaneously Reported Adverse Drug Reaction Data

Implementing the New Pharmacovigilance Legislation

European Risk Management

Pharmacovigilance Post July 2012 The new frontier

Qualification and validation: - an inspector s perspective. Ian Rees, Unit Manager Inspectorate Strategy

UK Standards for Pharmacovigilance Departments 2015

II.B.4. Information to be contained in the PSMF/ PSSF

Comparability: Regulatory Perspective

Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File

GVP Module X - additional monitoring of medicines

Guidance on preparing for Brexit in the centralised procedure

Trends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference

Role of International PVQA. Allison Jack, PVQA Director, GSK 24 th October 2017, Milan

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility

Concept paper submitted for public consultation. SANCO/D3/FS/cg/ddg1.d.3(2011)

EU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP

FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS

Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot

Quality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017

Early Access to Medicines Scheme (EAMS)

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington

Guideline on good pharmacovigilance practices (GVP)

Development Safety Update Report Guidance

Overview of the new pharmacovigilance legislation

MHRA GPvP Symposium Summary 6 November 2015 Novotel Hotel, London

Publication of Risk Management Plan (RMP) summaries:

Public Consultation (MLX 374): Transposition of Pharmacovigilance Directive 2010/84/EU

Guidelines for Pharmacovigilance Inspections

Der Stufenplanbeaufragte / die QPPV:

Pharmacovigilance: Information systems and Services

The new Pharmacovigilance legislation and implementation planning

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Consultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete.

Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)

Pharmacovigilance System in Russia and the EAEU

BULGARIAN ASSOCIATION FOR DRUG INFORMATION (BADI)

Signal Management in the EU and future extended access to EudraVigilance for industry

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group

EudraVigilance Registration Updates

Brexit Guidance for Stakeholders Human and veterinary medicines

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 03/08/2018 n/a. 25/07/2018 Labelling

CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS

Pharmacovigilance: Information systems and services

Q&A - Pharmacovigilance Legislation

Questions And Answers To Support The

EMA pharmacovigilance system manual

Report from EMA industry survey on Brexit preparedness

NIS Considerations - Bulgaria

IFAH-Europe considerations for greater efficiency of the Variations Regulation and associated guidelines

EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables

Implementation of EU Falsified Medicines Directive

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs

SPOR data management services - high level changes

Guide for Marketing Authorisation Holders on Direct Healthcare Professional Communications

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT

ECMC Annual Network meeting

EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change

Q&A ROYAL DECREE OF 28 MAY 2013 AND CIRCULAR LETTER N 601

Guidelines on good pharmacovigilance practices (GVP)

Ensuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader

Guidelines on good pharmacovigilance practices (GVP)

Good Documentation Practices. Documentation Requirements For Regulated Environments

Post Marketing PV AUDIT AND INSPECTION HOSTING. Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates

Good Pharmacovigilance Practice Tunisian guidelines

Good Vigilance Practice Module VI

Doc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021

QPPV Association and Training Part 2 Session Introduction

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Update on preparation for Signal Management

Functioning of the PRAC

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports

EudraVigilance auditable requirement project

Brexit info meeting. 5 February 2018

Presenter: Ejaz Butt

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

Transcription:

Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation Module II - Pharmacovigilance system master file Presented by: Joanna Harper Inspections, Enforcement & Standards Division (MHRA) An agency of the European Union

GVP Module II - Registration and Maintenance of PSMF Note: although applicants for THMP registrations will not have to include a PV system summary in the application, article 104 still applies in that a PSMF will need to be made available and maintained. PV system summary Location Registration Transfer from DDPS Variations Transfer of responsibilities for the PSMF

GVP Module II - Registration and Maintenance of PSMF PV System Summary Location there is a change following consultation on the implementing measures, from QPPV site to either at the site where the main pharmacovigilance activities are performed or at the site where the QPPV operates. This must also be a physical address for the MAH or contracted third party, within the Union. Therefore, the most relevant EU site should be selected, the default being the QPPV site in the absence of an appropriate site for selection. What considerations for guidance should be included for determination of main site?

Simplification the concept (past) Regulators MAH Validation Assessment MA Variation DDPS DDPS MA Variation DDPS DDPS MA Variation DDPS DDPS Variations required for DDPS updates include: QPPV change, QPPV contact details change, back up of QPPV, change in the safety database, change in contractual arrangements, topics covered by written procedures, PV sites, (other) (CI.9 of variations classification guideline)

Simplification the concept (future) Regulators MAH Validation Assessment MAs Master File Variation Article 8 System Summary requires: - QPPV contact details - PSMF location (+ article 57 database) Ongoing maintenance The PSMF will be kept up to date without variations. Variations will be required only for changes to the pharmacovigilance system summary (Article 8)

Module II PSMF, Registration and Maintenance Use of the article 57 database how can we optimize the use of the database? For example, it is proposed that once the article 57 database is in full use, PSMF location changes by variation may be limited to country changes only, with the database maintained for the full details. Changes to the variations classification guideline: removing the need for variations relating to PV system change when a PSMF is in place MAHs must still be prepared to submit PV system information and change information to allow NCAs and EMA to assess risk (included in the objectives, transfers of responsibilities and change control sections of the Module). This may be a full PSMF (including a pre-authorisation PSMF), the history of changes, or other relevant details)

Module II PSMF, Registration and Maintenance Early adoption of PSMF: Where no renewal is due, it is possible for MAHs to include a PSMF location in the marketing authorisation by variation (and therefore be relieved of DDPS requirements where applicable). This can occur before the end of the transition period (before July 2015). - In the period up to 2015, what will be the voluntary uptake of PSMF? - Is it clear that, in the instance of no renewal between July 2012 and 2015, variations to update the marketing authorisation (PV system summary) will have to be submitted for all products (except THMP)? What additional transitional guidance for the PSMF is required?

Module II PSMF, Representation of PV systems Arrangements for shared systems and delegated activities are described - Single PSMF per system - Single location per PSMF - Possibilities of more than one system (and PSMF) per MAH - Defining responsibilities (and QPPV) for shared systems in written agreements - MAH able to provide information about the PV system (PSMFs) applicable to entire portfolio of MAs What organisational arrangements and practical aspects do Industry want to see specifically covered in guidance?

Module II PSMF, Information contained in the PSMF QPPV details Products Organisational structure Sources of safety data Computerised systems and databases Processes PV system performance Quality System Annexes (lists) The maintenance of the information is described in the section on change control. Is additional guidance needed for the content sections? The format is deliberately unspecified so that existing systems can be used to generate content, would Industry prefer a template approach?

Module II PSMF, Change control - Informing QPPV and third parties/partners of significant changes: Safety database or associated databases, validation status (including data), Service provision for pharmacovigilance, Major contractual arrangements concerning PV, Mergers, acquisitions, PV sites, PSMF management. Changes to be notified to the QPPV are also in the section transfer of responsibilities : Changes that must be submitted as variations, The addition of corrective and/or preventative actions and managed deviations, Changes that affect oversight of the PV system in terms of capacity, functioning and compliance, Changes in the arrangements for providing the PSMF to NCAs, The addition of new products to the PV system.

Module II PSMF, Change control - Maintaining, and making accessible, records of change control for lists and documents - History of changes in a logbook for re-versioning of PSMF or significant changes Records of change for PSMF content will need to be maintained by the MAH, and may be requested by NCAs / Agency. Do the types of changes to be recorded in the logbook require further definition?

Simplification operational A uniform information set describing the pharmacovigilance system is available to the QPPV and for the purposes of audit. Tool for QPPV to oversee and manage system. There is a reduced burden in terms of documentation submitted as part of the MAA, for MAHs and NCAs: version control, storage. Less routine assessment of the system description: a practical reference for inspection and audit There will be a harmonised and consistent PSMF for NCAs to use to plan inspections, MAHs will not necessarily need to manage ad hoc versions of pre-inspection documentation. Opportunity to use existing systems and to generate content for submission when requested

What can we do to maximise the guidance?

Crown copyright 2012 The materials featured within this MHRA presentation are subject to Crown copyright protection. Any other copy or use of Crown copyright materials featured in this presentation, in any form or medium, is subject to prior approval of the MHRA which has Delegated Authority from Her Majesty's Stationery Office (HMSO) to administer Crown copyright for MHRA originated material. Applications should be in writing, clearly stating the proposed use/reuse of the information, and should be sent to the MHRA at the following address: Corporate Communications, 4.T, MHRA, 151 Buckingham Palace Road, Victoria, London, SW1W 9SZ or e-mail speakers@mhra.gsi.gov.uk. You may not sell or resell any information reproduced to any third party without prior agreement. The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned.